Murepavadin

Last updated
Murepavadin
Murepavadin structure.svg
Clinical data
Other namesPOL7080
Identifiers
  • (5aR,11S,14S,17S,20S,23S,26S,29R,32S,35S,38S,41S,44S,46aS)-17,20,26,29,35-Pentakis(2-aminoethyl)-32-(3-aminopropyl)-38-[(2S)-2-butanyl]-44-[(1R)-1-hydroxyethyl]-11-(hydroxymethyl)-23,41-bis(1H-indol-3 -ylmethyl)-14-methyltriacontahydro-1H,5H-dipyrrolo[1,2-a:1',2'-d][1,4,7,10,13,16,19,22,25,28,31,34,37,40]tetradecaazacyclodotetracontine-5,10,13,16,19,22,25,28,31,34,37,40,43,46(46aH)-tetradecone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C73H112N22O16
Molar mass 1553.837 g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)Cc4c[nH]c5c4cccc5)[C@@H](C)O)CO)C)CCN)CCN)Cc6c[nH]c7c6cccc7)CCN)CCN)CCCN)CCN
  • InChI=1S/C73H112N22O16/c1-5-38(2)58-70(108)88-52(24-30-79)65(103)83-47(17-10-25-74)62(100)85-49(21-27-76)63(101)86-51(23-29-78)66(104)89-53(33-41-35-80-45-15-8-6-13-43(41)45)67(105)87-50(22-28-77)64(102)84-48(20-26-75)61(99)82-39(3)60(98)91-55(37-96)72(110)95-32-12-19-57(95)73(111)94-31-11-18-56(94)69(107)93-59(40(4)97)71(109)90-54(68(106)92-58)34-42-36-81-46-16-9-7-14-44(42)46/h6-9,13-16,35-36,38-40,47-59,80-81,96-97H,5,10-12,17-34,37,74-79H2,1-4H3,(H,82,99)(H,83,103)(H,84,102)(H,85,100)(H,86,101)(H,87,105)(H,88,108)(H,89,104)(H,90,109)(H,91,98)(H,92,106)(H,93,107)/t38-,39-,40+,47-,48-,49+,50-,51-,52-,53-,54-,55-,56-,57+,58-,59-/m0/s1
  • Key:RIDRXGOBXZLKHZ-NZUANIILSA-N

Murepavadin also known as POL7080 is a Pseudomonas specific peptidomimetic antibiotic. [1] It is a synthetic cyclic beta hairpin peptidomimetic based on the cationic antimicrobial peptide protegrin I (PG-1) and the first example of an outer membrane protein-targeting antibiotic class with a novel, nonlytic mechanism of action, highly active and selective against the protein transporter LptD of Pseudomonas aeruginosa . [2] In preclinical studies the compound was highly active on a broad panel of clinical isolates including multi-drug resistant Pseudomonas bacteria with outstanding in vivo efficacy in sepsis, lung, and thigh infection models. [3] Intravenous murepavadin is in development [1] for the treatment of bacterial hospital-acquired pneumonia and bacterial ventilator-associated pneumonia due to Pseudomonas aeruginosa.

Contents

Discovery and structure

The host defense antimicrobial peptide protegrin I (PG-1), exhibits broad-spectrum antimicrobial activity and good activity against multi-drug resistant Gram-negative pathogens, with a mechanism consistent with membrane disruption via pore formation. However, PG-1 exhibits unfavorable drug properties and also exhibits significant hemolysis and, as such, has limited clinical use. PG-1 contains 18 amino acids and is ordered into an anti-parallel β-strand by two disulfide bridges. A fully synthetic cyclic peptide-like molecule containing a D-proline–L-proline template grafted into a peptidomimetic scaffold to simulate and stabilize the beta hairpin conformation exhibited by PG-1 was used to generate a diverse library of peptidomimetic macrocycles which were screened for antibacterial activity. [4] [5] [6] [7] Variants in this 14-residue protein epitope mimetic (PEM) library such as the peptidomimetic L8-1 had an antimicrobial activity like that of PG-1 but with reduced hemolytic activity on human red blood cells. [4] [5] Iterative rounds of synthesis generated analogues with an increasingly potent and selective profile producing nanomolar range compounds specifically against Pseudomonas spp. at the expense of broad-spectrum activity. [8] Final optimization led to the discovery of murepavadin, [1] [2] with remarkable Pseudomonas-specific activity in vitro and in vivo that has high plasma stability across species and is non-hemolytic at 100 μg/mL. Structure–activity relationship (SAR) studies showed that aromatic side chains of Trp2 and Trp8 are very important for antibiotic activity, [9] while nuclear magnetic resonance studies showed that these potent D-pro-L-pro antibiotic derivatives had a stable β- hairpin conformation in aqueous solution whereas related derivatives with the D-pro-L-pro template inverted to L-pro-D-pro, shows no stable hairpin conformation and the antimicrobial activity was lost, [9] suggesting that the β-hairpin structure is crucial for interaction with the bacterial target.

Design of a novel synthetic cyclic beta hairpin peptidomimetic based on the cationic antimicrobial peptide protegrin I Discovery of Murepavadin.svg
Design of a novel synthetic cyclic beta hairpin peptidomimetic based on the cationic antimicrobial peptide protegrin I

Mechanism of action

Murepavadin functions through a novel mechanism of action by binding to the lipopolysaccharide transport protein D (LptD), an outer membrane protein involved in lipopolysaccharide biogenesis in Gram-negative bacteria. [2] By binding to LptD, murepavadin inhibit the lipopolysaccharide transport function of LptD and causes lipopolysaccharide alterations in the outer membrane of the bacterium and, ultimately, cell death.

Spectrum of activity

Murepavadin exhibits a specific and potent bactericidal activity in vitro against Pseudomonas aeruginosa including carbapenemase-producing and colistin-resistant isolates and was shown to be largely inactive against other Gram-negative bacteria, and Gram-positive bacteria. When tested in a large minimum inhibitory concentration surveillance study, against 1219 contemporary clinical isolates from the USA, Europe, and China of which 28% were multi-drug resistant strains, murepavadin exhibited a potent antimicrobial activity having a minimum inhibitory concentration for 90% of strains of 0.12 mg/L. [1] There were no significant differences between geographic locations, and there was little difference in activity between multi-drug resistant/and non-multi-drug resistant isolates and no cross-resistance was observed with any other antimicrobial tested which supports its novel mechanism of action. Murepavadin showed outstanding in vivo efficacy in mouse sepsis (ED50 of 0.25 - 0.55 mg/kg) and lung and thigh infection models. It displays linear pharmacokinetics, is dose proportional with a good penetration into the epithelial lung fluid which underscores its potent in vivo activity in lung infection models including extensively drug-resistant isolates. In phase I clinical trial in healthy volunteers, single doses were well tolerated at plasma concentrations expected to meet or exceed efficacious levels, with no serious adverse events reported. [3] The favorable in vitro and in vivo properties of murepavadin combined with an appropriate safety pharmacology and toxicology profile led to the clinical development of murepavadin for the treatment of serious infections caused by Pseudomonas aeruginosa. Murepavadin successfully completed phase-II clinical tests in hospital patients with life-threatening Pseudomonas lung infections [8] and is in phase III development for the treatment of bacterial hospital-acquired and ventilator-associated bacterial due to Pseudomonas aeruginosa infection. [1]

Related Research Articles

<span class="mw-page-title-main">Cephalosporin</span> Class of pharmaceutical drugs

The cephalosporins are a class of β-lactam antibiotics originally derived from the fungus Acremonium, which was previously known as Cephalosporium.

<span class="mw-page-title-main">Aztreonam</span> Chemical compound

Aztreonam, sold under the brand name Azactam among others, is an antibiotic used primarily to treat infections caused by gram-negative bacteria such as Pseudomonas aeruginosa. This may include bone infections, endometritis, intra abdominal infections, pneumonia, urinary tract infections, and sepsis. It is given by intravenous or intramuscular injection or by inhalation.

<span class="mw-page-title-main">Colistin</span> Antibiotic

Colistin, also known as polymyxin E, is an antibiotic medication used as a last-resort treatment for multidrug-resistant Gram-negative infections including pneumonia. These may involve bacteria such as Pseudomonas aeruginosa, Klebsiella pneumoniae, or Acinetobacter. It comes in two forms: colistimethate sodium can be injected into a vein, injected into a muscle, or inhaled, and colistin sulfate is mainly applied to the skin or taken by mouth. Colistimethate sodium is a prodrug; it is produced by the reaction of colistin with formaldehyde and sodium bisulfite, which leads to the addition of a sulfomethyl group to the primary amines of colistin. Colistimethate sodium is less toxic than colistin when administered parenterally. In aqueous solutions it undergoes hydrolysis to form a complex mixture of partially sulfomethylated derivatives, as well as colistin. Resistance to colistin began to appear as of 2015.

<span class="mw-page-title-main">Meropenem</span> Broad-spectrum antibiotic

Meropenem, sold under the brand name Merrem among others, is an intravenous carbapenem antibiotic used to treat a variety of bacterial infections. Some of these include meningitis, intra-abdominal infection, pneumonia, sepsis, and anthrax.

<span class="mw-page-title-main">Piperacillin</span> Antibiotic medication

Piperacillin is a broad-spectrum β-lactam antibiotic of the ureidopenicillin class. The chemical structure of piperacillin and other ureidopenicillins incorporates a polar side chain that enhances penetration into Gram-negative bacteria and reduces susceptibility to cleavage by Gram-negative beta lactamase enzymes. These properties confer activity against the important hospital pathogen Pseudomonas aeruginosa. Thus piperacillin is sometimes referred to as an "anti-pseudomonal penicillin".

<i>Pseudomonas aeruginosa</i> Species of bacterium

Pseudomonas aeruginosa is a common encapsulated, Gram-negative, aerobic–facultatively anaerobic, rod-shaped bacterium that can cause disease in plants and animals, including humans. A species of considerable medical importance, P. aeruginosa is a multidrug resistant pathogen recognized for its ubiquity, its intrinsically advanced antibiotic resistance mechanisms, and its association with serious illnesses – hospital-acquired infections such as ventilator-associated pneumonia and various sepsis syndromes. P. aeruginosa is able to selectively inhibit various antibiotics from penetrating its outer membrane - and has high resistance to several antibiotics, according to the World Health Organization P. aeruginosa poses one of the greatest threats to humans in terms of antibiotic resistance.

<span class="mw-page-title-main">Carbapenem</span> Class of highly effective antibiotic agents

Carbapenems are a class of very effective antibiotic agents most commonly used for treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents individually exhibit a broader spectrum of activity compared to most cephalosporins and penicillins. Furthermore, carbapenems are typically unaffected by emerging antibiotic resistance, even to other beta-lactams.

<span class="mw-page-title-main">Imipenem</span> Carbapenem antibiotic

Imipenem is a synthetic β-lactam antibiotic belonging to the carbapenems chemical class. developed by Merck scientists Burton Christensen, William Leanza, and Kenneth Wildonger in the mid-1970s. Carbapenems are highly resistant to the β-lactamase enzymes produced by many multiple drug-resistant Gram-negative bacteria, thus playing a key role in the treatment of infections not readily treated with other antibiotics. It is usually administered through intravenous injection.

<i>Stenotrophomonas maltophilia</i> Species of bacterium

Stenotrophomonas maltophilia is an aerobic, nonfermentative, Gram-negative bacterium. It is an uncommon bacterium and human infection is difficult to treat. Initially classified as Bacterium bookeri, then renamed Pseudomonas maltophilia, S. maltophilia was also grouped in the genus Xanthomonas before eventually becoming the type species of the genus Stenotrophomonas in 1993.

β-Lactamase inhibitor Family of enzymes

Beta-lactamases are a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. In bacterial resistance to beta-lactam antibiotics, the bacteria have beta-lactamase which degrade the beta-lactam rings, rendering the antibiotic ineffective. However, with beta-lactamase inhibitors, these enzymes on the bacteria are inhibited, thus allowing the antibiotic to take effect. Strategies for combating this form of resistance have included the development of new beta-lactam antibiotics that are more resistant to cleavage and the development of the class of enzyme inhibitors called beta-lactamase inhibitors. Although β-lactamase inhibitors have little antibiotic activity of their own, they prevent bacterial degradation of beta-lactam antibiotics and thus extend the range of bacteria the drugs are effective against.

<span class="mw-page-title-main">Ceftobiprole</span> Chemical compound

Ceftobiprole, sold under the brand name Zevtera among others, is a fifth-generation cephalosporin antibacterial used for the treatment of hospital-acquired pneumonia and community-acquired pneumonia. It is marketed by Basilea Pharmaceutica under the brand names Zevtera and Mabelio. Like other cephalosporins, ceftobiprole exerts its antibacterial activity by binding to important penicillin-binding proteins and inhibiting their transpeptidase activity which is essential for the synthesis of bacterial cell walls. Ceftobiprole has high affinity for penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus strains and retains its activity against strains that express divergent mecA gene homologues. Ceftobiprole also binds to penicillin-binding protein 2b in Streptococcus pneumoniae (penicillin-intermediate), to penicillin-binding protein 2x in Streptococcus pneumoniae (penicillin-resistant), and to penicillin-binding protein 5 in Enterococcus faecalis.

<span class="mw-page-title-main">Arbekacin</span> Antibiotic

Arbekacin (INN) is a semisynthetic aminoglycoside antibiotic which was derived from kanamycin. It is primarily used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin was originally synthesized from dibekacin in 1973 by Hamao Umezawa and collaborators. It has been registered and marketed in Japan since 1990 under the trade name Habekacin. Arbekacin is no longer covered by patent and generic versions of the drug are also available under such trade names as Decontasin and Blubatosine.

Protegrins are small peptides containing 16-18 amino acid residues. Protegrins were first discovered in porcine leukocytes and were found to have antimicrobial activity against bacteria, fungi, and some enveloped viruses. The amino acid composition of protegrins contains six positively charged arginine residues and four cysteine residues. Their secondary structure is classified as cysteine-rich β-sheet antimicrobial peptides, AMPs, that display limited sequence similarity to certain defensins and tachyplesins. In solution, the peptides fold to form an anti-parallel β-strand with the structure stabilized by two cysteine bridges formed among the four cysteine residues. Recent studies suggest that protegrins can bind to lipopolysaccharide, a property that may help them to insert into the membranes of gram-negative bacteria and permeabilize them.

Multidrug resistant Gram-negative bacteria are a type of Gram-negative bacteria with resistance to multiple antibiotics. They can cause bacteria infections that pose a serious and rapidly emerging threat for hospitalized patients and especially patients in intensive care units. Infections caused by MDR strains are correlated with increased morbidity, mortality, and prolonged hospitalization. Thus, not only do these bacteria pose a threat to global public health, but also create a significant burden to healthcare systems.

Arenicins are a group of antimicrobial peptides being studied to combat Gram-negative bacteria.

Carbapenem-resistant Enterobacteriaceae (CRE) or carbapenemase-producing Enterobacteriaceae (CPE) are Gram-negative bacteria that are resistant to the carbapenem class of antibiotics, considered the drugs of last resort for such infections. They are resistant because they produce an enzyme called a carbapenemase that disables the drug molecule. The resistance can vary from moderate to severe. Enterobacteriaceae are common commensals and infectious agents. Experts fear CRE as the new "superbug". The bacteria can kill up to half of patients who get bloodstream infections. Tom Frieden, former head of the Centers for Disease Control and Prevention has referred to CRE as "nightmare bacteria". Examples of enzymes found in certain types of CRE are KPC and NDM. KPC and NDM are enzymes that break down carbapenems and make them ineffective. Both of these enzymes, as well as the enzyme VIM have also been reported in Pseudomonas.

Brilacidin, an investigational new drug, is a polymer-based antibiotic currently in human clinical trials, and represents a new class of antibiotics called host defense protein mimetics, or HDP-mimetics, which are non-peptide synthetic small molecules modeled after host defense peptides (HDPs). HDPs, also called antimicrobial peptides, some of which are defensins, are part of the innate immune response and are common to most higher forms of life. As brilacidin is modeled after a defensin, it is also called a defensin mimetic.

<span class="mw-page-title-main">Ceftolozane/tazobactam</span> Antibiotic

Ceftolozane/tazobactam, sold under the brand name Zerbaxa, is a fixed-dose combination antibiotic medication used for the treatment of complicated urinary tract infections and complicated intra-abdominal infections in adults. Ceftolozane is a cephalosporin antibiotic, developed for the treatment of infections with gram-negative bacteria that are resistant to conventional antibiotics. It was studied for urinary tract infections, intra-abdominal infections and ventilator-associated bacterial pneumonia.

<span class="mw-page-title-main">Ceftazidime/avibactam</span> Combination antibiotic medication

Ceftazidime/avibactam, sold under the brand name Avycaz among others, is a fixed-dose combination medication composed of ceftazidime, a cephalosporin antibiotic, and avibactam, a β-lactamase inhibitor. It is used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia. It is only recommended when other options are not appropriate. It is given by infusion into a vein.

<span class="mw-page-title-main">Cefiderocol</span> Antibiotic

Cefiderocol, sold under the brand name Fetroja among others, is an antibiotic used to treat complicated urinary tract infections when no other options are available. It is indicated for the treatment of multi-drug-resistant Gram-negative bacteria including Pseudomonas aeruginosa. It is given by injection into a vein.

References

  1. 1 2 3 4 5 Martin-Loeches I, Dale GE, Torres A (February 2018). "Murepavadin: a new antibiotic class in the pipeline". Expert Review of Anti-infective Therapy. 16 (4): 259–268. doi:10.1080/14787210.2018.1441024. PMID   29451043. S2CID   3482781.
  2. 1 2 3 Srinivas N, Jetter P, Ueberbacher BJ, Werneburg M, Zerbe K, Steinmann J, Van der Meijden B, Bernardini F, Lederer A, Dias RL, Misson PE, Henze H, Zumbrunn J, Gombert FO, Obrecht D, Hunziker P, Schauer S, Ziegler U, Kach A, Eberl L, Riedel K, DeMarco SJ, Robinson JA (February 2010). "Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa" (PDF). Science. 327 (5968): 1010–1013. Bibcode:2010Sci...327.1010S. doi:10.1126/science.1182749. PMID   20167788. S2CID   430525.
  3. 1 2 Wach A, Dembowsky K, Dale GE (April 2018). "Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses". Antimicrobial Agents and Chemotherapy. 62 (4): e02355-17. doi:10.1128/AAC.02355-17. PMC   5913942 . PMID   29437621.
  4. 1 2 Shankaramma SC, Athanassiou Z, Zerbe O, Moehle K, Mouton C, Bernardini F, Vrijbloed JW, Obrecht D, Robinson JA (November 2002). "Macrocyclic hairpin mimetics of the cationic antimicrobial peptide protegrin I: a new family of broad‐spectrum antibiotics". ChemBioChem. 3 (11): 1126−1133. doi:10.1002/1439-7633(20021104)3:11<1126::AID-CBIC1126>3.0.CO;2-I. PMID   12404639. S2CID   30100906.
  5. 1 2 Robinson JA, Shankaramma SC, Jetter P, Kienzl U, Schwendener RA, Vrijbloed JW, Obrecht D (March 2005). "Properties and structure–activity studies of cyclic β-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I". Bioorganic & Medicinal Chemistry. 13 (6): 2055–2064. doi:10.1016/j.bmc.2005.01.009. PMID   15727859.
  6. ↑ Luther A, Moehle K, Chevalier E, Dale G, Obrecht D (January 2011). "Emerging new therapeutics against key Gram-negative pathogens". Annual Reports in Medicinal Chemistry. 46: 245–262. doi:10.1016/B978-0-12-386009-5.00012-6. ISBN   9780123860095.
  7. ↑ Robinson JA, Shankaramma SC, Jetter P, Kienzl U, Schwendener RA, Vrijbloed JW, Obrecht D (June 2017). "Protein epitope mimetic macrocycles as biopharmaceuticals". Current Opinion in Chemical Biology. 38: 45–51. doi:10.1016/j.cbpa.2017.02.004. PMID   28319811.
  8. 1 2 Zerbe K, Moehle K, Robinson JA (June 2017). "Protein Epitope Mimetics: From New Antibiotics to Supramolecular Synthetic Vaccines". Accounts of Chemical Research. 50 (6): 1323−1331. doi:10.1021/acs.accounts.7b00129. PMID   28570824.
  9. 1 2 Schmidt J, Patora-Komisarska K, Moehle K, Obrecht D, Robinson JA (September 2013). "Structural studies of β-hairpin peptidomimetic antibiotics that target LptD in Pseudomonas sp" (PDF). Bioorganic & Medicinal Chemistry. 21 (18): 5806−5810. doi:10.1016/j.bmc.2013.07.013. PMID   23932450.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.